Overview of Rimso-50

Quick Facts

Property	Description
Active ingredient	Dimethyl Sulfoxide (DMSO)
Form	50% Aqueous Solution
Pharmacological class	Urinary Analgesic
Typical use	Symptomatic relief of bladder discomfort
Origin	Synthetic

What Type of Medication is Rimso-50?

Rimso-50 is a prescription-only pharmaceutical agent, defined by its active chemical substance, Dimethyl Sulfoxide (DMSO), a highly polar synthetic compound. The medication is classified as a urinary analgesic, a specific group of medicines targeting pain in the urinary system, and falls under the broader category of miscellaneous genitourinary tract agents. DMSO functions as a local anti-inflammatory agent, underscoring its specialized therapeutic role.

Composition and Formulation: The Role of Dimethyl Sulfoxide

Rimso-50 is characterized by its precise composition as a single product in a 50% w/w aqueous solution, designed exclusively for the intravesical instillation route, where it is delivered directly into the bladder via a catheter. Unlike oral or injectable medications, the solution formulation is critical; it enables the molecule to act as a powerful membrane penetrant. This unique characteristic ensures the active substance can bypass superficial layers to reach the deeper tissues of the bladder wall.

High-Level Purpose and Key Actions

The overarching purpose of Rimso-50 is to provide symptomatic relief for chronic discomfort and pain localized specifically within the bladder. This relief is achieved through the compound's combined penetrant capability with its inherent analgesic and anti-inflammatory effects. The focused application avoids systemic exposure, offering a distinguishing factor for this medication when addressing persistent bladder irritation.

What side effects are possible with Rimso-50?

Possible side effects and safety information

Officially Documented Adverse Reactions

The official product labeling identifies adverse reactions based on their nature and the organ systems affected, as classified in regulatory documents. These effects are generally grouped into sensory, local, and immune categories.

Sensory and Local Effects: The most commonly documented reactions relate to the administration method and the drug's metabolism. Patients may experience a garlic-like taste in the mouth and a distinctive odor on the breath and skin, which may persist for up to 72 hours. Pain or discomfort upon instillation is also documented, which typically lessens with repeated treatments.
Genitourinary Effects: These include temporary reactions such as transient chemical cystitis and local bladder discomfort.
Serious Immune Reactions: While rare, official regulatory documents note the possibility of a hypersensitivity or anaphylactoid reaction.

Mandatory Safety Considerations and Monitoring

Certain safety parameters are required by regulatory authorities for patient monitoring during treatment:

Systemic and Organ Monitoring: Periodic biochemical screening, particularly of liver and renal function, and a complete blood count are recommended during the course of therapy. Due to findings in non-human studies, full ophthalmic evaluations, including slit lamp examinations, are also required prior to and periodically throughout treatment.
Population Notes: The medication is classified as Pregnancy Category C; use in pregnant or nursing patients requires caution. Safety and effectiveness for pediatric patients have not been established.
Use Limitations: Instillation may be harmful to individuals with existing urinary tract malignancy. Furthermore, the active substance has been noted to potentially potentiate other concomitantly administered medications.

Overdose and Emergency Response

Rimso-50 Overdose and when to seek help — official regulatory information

The official regulatory profile for Dimethyl Sulfoxide (Rimso-50) focuses on the potential for severe acute reactions rather than a traditional dose-dependent overdose toxicity.

Overdose Scope

The primary documented acute manifestation requiring emergency intervention is the development of anaphylactoid symptoms, which result from a severe systemic hypersensitivity reaction. These serious outcomes are associated with the potential for histamine liberation following administration. The physiological systems potentially affected are those subject to the consequences of a severe systemic reaction. The official labeling does not specify any acute dose-related factors for a classic overdose syndrome. Similarly, specific notes on overdose management for different patient populations are not detailed in the acute overdose information.

Immediate Emergency Response

When acute severe manifestations occur, the regulatory documents mandate that immediate medical attention must be sought. The official requirement states that appropriate therapy should be instituted immediately if anaphylactoid symptoms develop during or after the procedure. This regulatory basis establishes the potential for a life-threatening outcome associated with the hypersensitivity reaction, necessitating urgent therapeutic intervention. The official documentation does not explicitly detail the existence of a specific antidote or list specific supportive measures like gastric lavage.

Connection to the overall overdose profile

The official profile defines the emergency condition based on the mandated requirement to manage a severe hypersensitivity reaction. This structure ensures that immediate action is taken if anaphylactoid symptoms appear, as directed by the government-authorized prescribing information.

Therapeutic Uses of Rimso-50

Rimso-50 is commonly used to help with the symptomatic relief of patients experiencing Interstitial Cystitis (IC). This medication is considered relevant for managing conditions presenting with systemic or localized discomfort. The medicine is generally used for the relief of adult patients experiencing symptoms related to physical discomfort.

This medication may be part of symptomatic management for conditions presenting with disruptive symptom manifestations. It is used for managing symptoms related to inflammatory or irritative states, such as chronic localized pain, persistent bladder pressure, urinary urgency, and frequency. The use of this medicine may assist with maintaining functional stability.

The medicine is generally relevant when symptoms become more noticeable and when short-term symptomatic assistance is needed. This supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load.

Quick Fact: Relief for Chronic Bladder Pain

Focus Area	Symptom Category	Patient Benefit
Primary Indication	Interstitial Cystitis (IC)	Supports general well-being
Symptom Cluster	Pain, Pressure, Urgency	Contributes to improved comfort
Clinical Context	Refractory/Chronic Symptoms	Assists with functional stability

Regulatory References

Health Canada Product Monograph

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Rimso-50 — Official Regulatory Information

The eligibility for Rimso-50 is strictly defined by regulatory documents, focusing primarily on the adult population and specific physiological restrictions.

Eligibility Scope	Regulatory Status	Classification
Populations Allowed	Adults (18 years and older) are the population with established use.	Established Use
Populations Contraindicated	None known in primary labeling; use is prohibited in cases of hypersensitivity to Dimethyl Sulfoxide (DMSO).	Absolute Contraindication
Age-Related Rules	Safety and effectiveness have not been established in children (pediatric patients).	Not Established
Pregnancy Status	Pregnancy Category C. Use is restricted and only permitted if the potential benefit justifies the potential risk to the fetus.	Conditional Use
Lactation Status	Caution must be exercised; it is not known whether the drug is excreted in human milk.	Conditional Use

Condition-Specific Eligibility Rules

The medicine is used with significant caution or is not recommended in patients with a known or suspected urinary tract malignancy, such as bladder or kidney cancer, due to the drug’s vasodilatory properties. For patients receiving long-term treatment, continued eligibility is conditional upon mandatory periodic eye examinations and biochemical screening (liver and renal function tests) approximately every six months.

What should I know about interactions with other medicines?

Rimso-50's interaction profile is officially defined by specific restrictions on co-administration, documented effects on drug exposure, and mandated procedural timing requirements. All statements are based strictly on government regulatory documentation.

Formal Restrictions and Major Interactions

Regulatory documents establish formal restrictions regarding co-administration with certain medicinal products. The combination with Sulindac is classified as a major interaction and is restricted because it reduces the plasma concentrations of Sulindac's active sulfide metabolite, potentially leading to reduced efficacy. Furthermore, the combination with Dexrazoxane is classified as a high-risk combination in relevant therapeutic contexts, as Dimethyl Sulfoxide may diminish the therapeutic effect of the drug.

Exposure- and Efficacy-Altering Effects

The official labeling includes a general warning that Dimethyl Sulfoxide may potentiate (increase the action or effects of) other medicines administered concurrently. This general statement suggests a potential for altered exposure of co-administered drugs. A moderate interaction is documented with Verteporfin, as Dimethyl Sulfoxide may decrease the photodynamic agent’s efficacy. This effect is described in regulatory summaries as an antagonism of Verteporfin's activity.

Mandated Administration Sequence

The official label defines a procedural constraint related to the co-administration of certain antispasmodic agents. Specific oral analgesics or suppositories, such as those containing Belladonna and Opium, may be administered prior to instillation of Rimso-50. This is documented to assist with managing potential bladder spasm during the procedure. No specific interactions with food, alcohol, or herbal products are documented in the official labeling.

Mechanism of Action

The mechanism of action for Dimethyl Sulfoxide (DMSO) is multifaceted and operates exclusively at the local tissue level within the bladder wall. The molecule's amphipathic nature allows it to function as a membrane penetrant, rapidly diffusing across the urothelial lining to achieve high concentrations in the underlying submucosal tissue and nerve bundles. This physical-chemical property is essential for engaging deeper targets. DMSO exerts an anti-inflammatory effect primarily by acting as a free-radical scavenger, chemically neutralizing destructive hydroxyl radicals ( OHcdot). It also suppresses key inflammatory signaling cascades and modulates the release of pro-inflammatory cytokines. This dual molecular action limits oxidative stress and modulates pathways associated with localized vascular dynamics. Furthermore, DMSO interacts directly with nociceptive C-Afferent nerve fibers in the tissue. This interaction modulates or impairs the nerve's ability to propagate electrical signals, causing a transient blockade of nerve conduction. The resulting physiological consequence is the attenuation of sensory signal transmission, which reduces afferent nociceptive input from the tissue.

Dosage and Administration Information

How to use Rimso-50 — Administration Guidelines

Rimso-50 (Dimethyl Sulfoxide 50% aqueous solution) is used for specialized administration. The method, volume, and frequency of its delivery require the solution to be introduced directly into the bladder.

Administration Scope

Element	Instruction
Route of administration	Intravesical Instillation (direct delivery into the bladder via catheter). It is designated as not for intramuscular or intravenous injection.
Standard Dosing Volume	A fixed dose of 50 mL of the 50% solution is instilled per treatment session.
Initial Frequency	Treatment is initially administered every two weeks.
Duration Pattern	The frequency is adjusted by lengthening the time between treatments once maximum symptomatic relief is obtained.

Procedural and Contextual Instructions

The solution is supplied as a sterile, non-pyrogenic 50 mL vial and is introduced using a catheter or asepto syringe. The administered dose is allowed to remain in the bladder for 15 minutes before being eliminated by spontaneous voiding.

To manage potential discomfort during the procedure, administration of oral analgesics or the use of an analgesic lubricant gel may occur prior to instillation. For patients exhibiting severe bladder sensitivity, initial treatments may be carried out under anesthesia.

Connection to the Overall Use Protocol

The protocol involves a specialized, localized treatment method, involving the direct Intravesical Instillation of a fixed 50 mL volume and a subsequent 15-minute retention time. The standardized dosing begins with an every two-week frequency, which is then adapted to a maintenance pattern with extended intervals based on the patient's individual response. These procedural requirements ensure the medication acts directly on the bladder wall.

Recent Clinical Evidence

Evidence for use in Interstitial Cystitis (IC) / Bladder Pain Syndrome (BPS)

Research regarding Rimso-50, which is administered as an intravesical instillation, has focused on evaluating how it affects patient-reported outcomes related to physical discomfort and daily functioning. Studies examined changes in symptoms such as bladder pain and urinary frequency in adult populations diagnosed with IC/BPS. The earliest research reports suggested that some patients reported relief following a course of treatment, contributing to the initial evidence base. More recent systematic reviews have explored the combined data from multiple studies and indicated an association between treatment and reductions in key symptom indices and pain scores from baseline. However, findings across all trials are not always consistent, and some comparative studies have reported significant dropout rates for patients receiving Rimso-50, often related to discomfort during administration.

Long-term studies and follow-up

Research has explored the effects of Rimso-50 beyond the initial short-term treatment period (typically 6 to 12 weeks). Some retrospective and observational studies have described symptom amelioration lasting for several months, or even years, in select patient groups following the initial course. However, long-term outcomes and the durability of response are not fully established by extensive, long-running randomized controlled trials. Research has not yet clearly characterized the need for or the impact of repeated maintenance therapy over many years. Therefore, the evidence base provides limited information on the full sustained impact over the lifetime of the condition.

What is still uncertain about Rimso-50

The current body of research contains several limitations. Sample sizes were often modest in earlier controlled trials, and evidence quality varies across studies. It is not yet clear which specific subtypes of IC/BPS patients are most likely to respond to the treatment, or how the outcome compares to the full range of newer therapeutic agents. Furthermore, data for certain groups remain insufficient, including adolescents or pregnant populations, as research has primarily focused on the general adult population. Research is ongoing to better understand the observed changes and the optimal treatment protocols.

Key Studies & References

A prospective randomized controlled multicentre trial comparing intravesical DMSO and chondroïtin sulphate 2% for painful bladder syndrome/interstitial cystitis

Frequently Asked Questions (FAQ)

Common questions about Rimso-50 (FAQ)

Q: Are there any long-term side effects associated with repeated Rimso-50 use?

Official documents describe that mandatory monitoring is required during the course of treatment. This includes periodic check-ups such as ophthalmic evaluations (eye exams) and liver and renal function tests to track systemic health. Research summaries also note that the long-term sustainability of symptom relief over many years is not fully established by extensive clinical trials.

Q: What is the chemical makeup of dimethyl sulfoxide (DMSO)?

Dimethyl sulfoxide (DMSO) is officially described in drug documents as a highly polar synthetic compound. The medication is formulated as a 50% aqueous solution, which means it is half DMSO and half water, prepared specifically for instillation into the bladder.

Q: Are there research studies comparing the effectiveness of Rimso-50 to placebo?

Research summaries indicate that clinical trials and systematic reviews have explored the drug’s effectiveness by examining patient-reported outcomes. While official texts do not provide specific details on the design of all studies, the overall evidence base examines patient outcomes by tracking changes from a patient’s starting point (baseline) and, in some contexts, comparing to other therapeutic approaches.

Q: What should be done if a patient misses a scheduled treatment appointment?

Official patient information describes that if a treatment is missed, it should generally be used as soon as the patient remembers, if possible. If it is close to the time for the next scheduled treatment, the information indicates that the missed treatment may be skipped, and the patient may proceed with the next scheduled treatment. The instructions note that doubling the treatment volume to compensate for a missed treatment is not recommended.

Q: Is Rimso-50 the same thing as over-the-counter or industrial DMSO?

No. Rimso-50 is the only formulation of dimethyl sulfoxide (DMSO) approved by the U.S. FDA specifically for treating interstitial cystitis. Authoritative sources explicitly state that other preparations of DMSO, such as those available for industrial or veterinary purposes, are not intended for human use due to unknown purity and unverified safety for medical applications.

Q: Is Rimso-50 an antibiotic or is it used to treat bladder infections?

Rimso-50 is officially classified as a urinary analgesic. Official FDA labeling and drug summaries explicitly state: there is no clinical evidence of effectiveness of this medicine in the treatment of bacterial infections of the urinary tract.

Q: Is it true that Rimso-50 is the only FDA-approved instillation for Interstitial Cystitis?

Authoritative patient information often describes Rimso-50 (DMSO 50% aqueous solution) as the first and only FDA-approved bladder instillation specifically for the treatment of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). The statement often refers to its status as a prescribed intravesical instillation.

Q: Is it possible for Rimso-50 to be used as part of a 'bladder cocktail' with other solutions?

Official labeling describes the use of oral analgesics or suppositories prior to the instillation. While the official product is a single-drug solution, patient information notes that healthcare providers commonly combine Rimso-50 with other instilled medicines, such as heparin or steroids, based on clinical practice.

Q: Why must the Rimso-50 treatment be done in a hospital or clinic setting?

Official instructions specify that the instillation must be performed by a healthcare professional using sterile equipment, such as a catheter or syringe. Furthermore, patients must be monitored for potential side effects, including hypersensitivity reactions, which requires the resources and oversight of a clinical setting.

Q: Can Rimso-50 be used for conditions other than Interstitial Cystitis (IC)?

No. The official FDA label explicitly states that Rimso-50 is indicated only for the symptomatic relief of interstitial cystitis. Regulatory documents indicate that the drug has not been approved for use in any other medical condition.

Q: Why do official documents state that Rimso-50 has not been approved for any other indication?

The official indication section of the drug’s labeling explains its approved use is solely for the symptomatic relief of interstitial cystitis. The official indication section is a regulatory statement that formally defines the specific condition (interstitial cystitis) for which the product’s use has been approved.

Q: Are there any known interactions between Rimso-50 and herbal supplements or vitamins?

The official drug labeling addresses potential interactions with specific prescription medicines. The label does not document any specific interactions with food, alcohol, or herbal products. This means official sources do not list known adverse interactions with these substances.

Q: What happens to Rimso-50 after it is placed in the bladder and before it is expelled?

After instillation, the active substance, DMSO, is absorbed into the bladder wall. The body then breaks it down into two primary metabolic compounds: dimethyl sulfone and dimethyl sulfide. These substances are subsequently eliminated through the urine, feces, breath, and skin.

Q: Can Rimso-50 treatments cause a temporary worsening or flare of IC symptoms?

The adverse reaction profile documents that patients may experience transient chemical cystitis and moderately severe discomfort upon administration. While the official texts do not use the term 'flare,' these documented reactions are local and can be transient.

Q: Does Rimso-50 contain any inactive ingredients that could cause an allergic reaction?

The medication is officially described as a 50% aqueous solution of dimethyl sulfoxide, meaning the primary components are the active drug and water. Warnings regarding allergic reactions focus on hypersensitivity to the active ingredient (DMSO) itself.

Q: Is the sensation of a garlic taste caused by the drug itself or its breakdown products?

Official labeling notes that the distinctive taste and odor are caused by the presence of a metabolite being eliminated from the body. Specifically, the garlic-like scent is attributed to dimethyl sulfide, a breakdown product excreted through the breath and skin.

Q: Does the effect of Rimso-50 wear off over time, requiring more frequent treatments?

Official dosing instructions state that treatment intervals should be increased once maximum symptomatic relief is obtained, aiming for a maintenance schedule. However, research summaries also note that the durability of the response over many years is not fully established by long-running trials.

Q: Is there a concern about the DMSO in Rimso-50 absorbing through the skin during administration?

The active compound, DMSO, has been noted in occupational safety data as a substance that easily penetrates the skin. For this reason, specific hygiene and safety procedures for healthcare professionals are documented for the handling and administration of the product.

How should Rimso-50 be stored and disposed of?

How to Store and Dispose of Rimso-50?

RIMSO-50 (dimethyl sulfoxide) must be stored under specific conditions mandated by regulatory agencies to maintain its stability and integrity.

Storage Conditions

Condition	Requirement
Temperature	Store at USP Controlled Room Temperature (20 to 25 C or 68 to 77 F).
Protection	Protect from strong light. Store in a cool, dry, and well-ventilated area.
Container Check	The sterile solution must be examined for discoloration or precipitate (solid particles) before use. Do not administer compromised product.

Disposal Instructions

Disposal of any unused or expired product must be done in accordance with all local, regional, national, and international regulations. The product must not be disposed of into the sewer or discharged into the wastewater system. All pharmaceuticals should be kept away from children.

Rimso-50